Drug-induced Fatty Liver Disease: Pathogenesis and Treatment

Metabolic dysfunction-associated fatty liver disease (commonly known as MAFLD) impacts global health in epidemic proportions, and the resulting morbidity, mortality and economic burden is enormous. While much attention has been given to metabolic syndrome and obesity as offending factors, a growing...

Descripción completa

Detalles Bibliográficos
Autores principales: Kolaric, Tea Omanovic, Nincevic, Vjera, Kuna, Lucija, Duspara, Kristina, Bojanic, Kristina, Vukadin, Sonja, Raguz-Lucic, Nikola, Wu, George Y, Smolic, Martina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: XIA & HE Publishing Inc. 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8516847/
https://www.ncbi.nlm.nih.gov/pubmed/34722188
http://dx.doi.org/10.14218/JCTH.2020.00091
Descripción
Sumario:Metabolic dysfunction-associated fatty liver disease (commonly known as MAFLD) impacts global health in epidemic proportions, and the resulting morbidity, mortality and economic burden is enormous. While much attention has been given to metabolic syndrome and obesity as offending factors, a growing incidence of polypharmacy, especially in the elderly, has greatly increased the risk of drug-induced liver injury (DILI) in general, and drug-induced fatty liver disease (DIFLD) in particular. This review focuses on the contribution of DIFLD to DILI in terms of epidemiology, pathophysiology, the most common drugs associated with DIFLD, and treatment strategies.

Ejemplares similares